» Articles » PMID: 21493797

Chronic GVHD Risk Score: a Center for International Blood and Marrow Transplant Research Analysis

Abstract

Several risk factors are associated with increased mortality in patients with chronic graft-versus-host disease (cGVHD), but there is considerable variability in the reported factors. Therefore, we evaluated patient, transplantation, and cGVHD characteristics to develop a risk score in 5343 patients with cGVHD. Ten variables were identified as being significant in multivariate analysis of overall survival and nonrelapse mortality (NRM): age, prior acute GVHD, time from transplantation to cGVHD, donor type, disease status at transplantation, GVHD prophylaxis, gender mismatch, serum bilirubin, Karnofsky score, and platelet count. These 10 variables were used to build a cGVHD risk score, and 6 risk groups (RGs) were identified. The 5-year NRM was 5% (1%-9%) in RG1, 20% (19%-23%) in RG2, 33% (29%-37%) in RG3, 43% (40%-46%) in RG4, 63% (53%-74%) in RG5, and 72% (59%-85%) in RG6. The 5-year overall survival was highest at 91% (95% confidence interval [CI]:85%-97%) in RG1, followed by 67% (65%-69%) in RG2, 51% (46%-55%) in RG3, 40% (37%-43%) in RG4, 21% (12%-30%) in RG5, and 4% (0%-9%) in RG6 (all P < .01). This analysis demonstrates the usefulness of data from a large registry to develop risk-score categories for major transplantation outcomes. Validation of this cGVHD risk score is needed in a different population to ensure its broad applicability.

Citing Articles

Clonal GZMKCD8 T cells are identified as a hallmark of the pathogenesis of cGVHD-induced bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.

Gao Y, Liu R, Shi J, Shan W, Zhou H, Chen Z EBioMedicine. 2024; 112:105535.

PMID: 39740295 PMC: 11750515. DOI: 10.1016/j.ebiom.2024.105535.


Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease.

Mahmoudjafari Z, Bhatt V, Galvin J, Xue Z, Zeiser R, Locatelli F Bone Marrow Transplant. 2024; 60(1):69-78.

PMID: 39506073 PMC: 11726446. DOI: 10.1038/s41409-024-02445-6.


Umbilical Cord Blood Platelet Lysate Eyedrops for the Treatment of Severe Ocular Surface Disorders in Graft vs. Host Disease Patients: Clinical Study.

Gagliano C, Foti R, Zeppieri M, Maniaci A, Lavalle S, Tancredi G Life (Basel). 2024; 14(10).

PMID: 39459568 PMC: 11509496. DOI: 10.3390/life14101268.


Oral Chronic Graft-Versus-Host Disease: Pathogenesis, Diagnosis, Current Treatment, and Emerging Therapies.

Nguyen J, Jessri M, Costa-da-Silva A, Sharma R, Mays J, Treister N Int J Mol Sci. 2024; 25(19).

PMID: 39408739 PMC: 11476840. DOI: 10.3390/ijms251910411.


[Chinese expert consensus on the diagnosis and treatment of chronic graft-versus-host disease (2024)].

Zhonghua Xue Ye Xue Za Zhi. 2024; 45(8):713-726.

PMID: 39307718 PMC: 11535560. DOI: 10.3760/cma.j.cn121090-20240611-00217.


References
1.
Vigorito A, Campregher P, Storer B, Carpenter P, Moravec C, Kiem H . Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood. 2009; 114(3):702-8. PMC: 2713471. DOI: 10.1182/blood-2009-03-208983. View

2.
Wingard J, Piantadosi S, Vogelsang G, Farmer E, Jabs D, Levin L . Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood. 1989; 74(4):1428-35. View

3.
Stewart B, Storer B, Storek J, Deeg H, Storb R, Hansen J . Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004; 104(12):3501-6. DOI: 10.1182/blood-2004-01-0200. View

4.
Gooley T, Leisenring W, Crowley J, Storer B . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999; 18(6):695-706. DOI: 10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o. View

5.
Sullivan K, Witherspoon R, Storb R, Weiden P, Flournoy N, Dahlberg S . Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988; 72(2):546-54. View